IMM 01

Drug Profile

IMM 01

Alternative Names: IMM-01

Latest Information Update: 04 Feb 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Immunova
  • Developer Modulate Therapeutics
  • Class Antineoplastics; Immunotherapies
  • Mechanism of Action Immunostimulants; Interleukin-2 receptor agonists; Transforming growth factor beta inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 01 Feb 2016 Eli Lilly has the option to acquire IMM-01 after completion of proof-of-concept studies
  • 01 Feb 2016 Preclinical trials in Cancer in Canada (Intratumoural) before February 2016
  • 01 Feb 2016 Immunova in-licenses nanoparticle delivery technology from Yale and John Hopkins University
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top